Share This Article:

Successful Management of a Complicated Ulcer Caused by Autoimmune Vasculitis, with Sildenafil Citrate in a Patient with Primary Antiphospholipid Syndrome and Transient Steroid-Induced Diabetes Mellitus: A Case Report and Literature Review

Abstract Full-Text HTML XML Download Download as PDF (Size:1455KB) PP. 189-193
DOI: 10.4236/jdm.2014.43027    2,919 Downloads   3,471 Views   Citations

ABSTRACT

Antiphospholipid syndrome (APS) is a prothrombotic condition that can affect both the venous circulation and the arterial system. The deep veins of the lower extremities and cerebral blood flow are the most common sites of venous and arterial thrombosis, respectively. Skin ulceration and gangrene may be associated with an active vasculitis in patients with APS. These kinds of ulcers are considered intractable because healing is difficult to achieve. Using steroids as immunesuppressant therapy is still a basic part of managing APS and vasculitis. Nevertheless, in the presence of steroid-induced diabetes mellitus, the priority is to achieve faster wound healing, because of the potential complications that can develop due to metabolic dysfunction and augmented vulnerability to infection. Until recently, there were few reports demonstrating the benefits of the use of adjuvant phosphodiesterase-5 inhibitors like sildenafil citrate in different clinical entities with courses like Raynaud’s phenomenon, scleroderma, and resistance to vasodilator therapy. We present the first report demonstrating the additional benefit of sildenafil citrate for the integration of grafts in a patient with steroid-induced diabetes and APS who had ulcers due to vasculitis resistant to the usual vasodilator therapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Grover-Páez, F. , García-Benavides, L. , Cardona-Muñóz, E. , Ramos-Becerra, C. , García-Corral, J. , Medina-García, C. , Alanis-Sánchez, G. and Totsuka-Sutto, S. (2014) Successful Management of a Complicated Ulcer Caused by Autoimmune Vasculitis, with Sildenafil Citrate in a Patient with Primary Antiphospholipid Syndrome and Transient Steroid-Induced Diabetes Mellitus: A Case Report and Literature Review. Journal of Diabetes Mellitus, 4, 189-193. doi: 10.4236/jdm.2014.43027.

References

[1] Brandt, J.T., Triplett, D.A., Alving, B. and Scharrer, I. (1995) Criteria for the Diagnosis of Lupus Anticoagulants: An Update. Thrombosis and Haemostasis, 74, 1185-1190.
[2] Miyakis, S., Lockshin, M.D., Atsumi, T., et al. (2006) International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295-306. http://dx.doi.org/10.1111/j.1538-7836.2006.01753.x
[3] Cervera, R., Piette, J.C., Font, J., et al. (2002) Antiphospholipid Syndrome: Clinical and Immunologic Manifestations and Patterns of Disease Expression in a Cohort of 1000 patients. Arthritis Rheumatology, 46, 1019-1027. http://dx.doi.org/10.1002/art.10187
[4] Vega-Ostertag, M., Casper, K., Swerlick, R., Ferrara, D., Harris, E.N. and Pierangeli, S.S. (2005) Involvement of p38 MAPK in the Up-Regulation of Tissue Factor on Endothelial Cells by Antiphospholipid Antibodies. Arthritis Rheumatology, 52, 1545-1554.
http://dx.doi.org/10.1002/art.21009
[5] Vega-Ostertag, M.E., Ferrara, D.E., Romay-Penabad, Z., Liu, X., Taylor, W.R., Colden-Stanfield, M., et al. (2007) Role of p38 Mitogen-Activated Protein Kinase in Antiphospholipid Antibody Mediated Thrombosis and Endothelial Cell Activation. Journal of Thrombosis and Haemostasis, 5, 1828-1834. http://dx.doi.org/10.1111/j.1538-7836.2007.02680.x
[6] Routy, B., Huynh, T., Fraser, R. and Séguin, C. (2013) Vascular Endothelial Cell Function in Catastrophic Antiphospholipid Syndrome: A Case Report and Review of the Literature. Case Reports in Hematology, 2013, Article ID: 710365.
[7] Lim, W. (2013) Antiphospholipid Syndrome. Hematology—American Society of Hematology Education Program, 2013, 675-680. http://dx.doi.org/10.1182/asheducation-2013.1.675
[8] Pudusseri, A., Shameem, R. and Spyropoulos, A.C. (2013) A New Paradigm Shift in Antithrombotic Therapy. Frontiers in Pharmacology, 4, 133. http://dx.doi.org/10.3389/fphar.2013.00133
[9] Kotila, T.R., Olutogun, T. and Ipadeola, A. (2013) Steroid Induced Diabetes Mellitus in Patients Receiving Prednisolone for Haematological Disorders. African Health Sciences, 13, 842-844
[10] Toyozawa, S., Yamamoto, Y., Kishioka, A., Yonei, N., Kanazawa, N., Matsumoto, Y., et al. (2009) Effective Treatment of Intractable Skin Ulcers Using Allogeneic Cultured Dermal Substitutes in Patients with Systemic Lupus Erythematosus. European Journal of Dermatology, 19, 594-596.
[11] Waqar, A.J., Habit, U.S., et al. (2009) Management of Diabetic Foot According to Wagner Classification and Frequency of Diabetic Foot Disease. Journal of Postgraduate Medical Institute, 23, 245-250.
[12] Schaffer, M.R., Tantry, U., van Wesep, R.A., et al. (1997) Nitric Oxide Metabolism in Wounds. Journal of Surgical Research, 71, 25. http://dx.doi.org/10.1006/jsre.1997.5137
[13] Mejia Terrazas, G.E., Plancarte Sanchez, R., Reyes Chiquete, D. and Guajardo Rosas, J. (2009) Eficacia y seguridad de catéteres epidurales en pacientes oncológicos terminales ambulatorios. Reporte de casos. Revista Brasileira de Anestesiologia, 32, 186-190.
[14] Toyozawa, S., Yamamoto, Y., Kishioka, A., Nozomi, Y., Kanazawa, N. and Yatsumoto, Y., et al. (2009) Effective Treatment of Intractable Skin Ulcers Using Allogeneic Cultured Dermal Substitutes in Patients with Systemic Lupus Erythematosus. European Journal of Dermatology, 19, 594-596.
[15] Giannakopoulos, B. and Krilis, S.A. (2013) The Pathogenesis of the Antiphospholipid Syndrome. The New England Journal of Medicine, 368, 1033-1044. http://dx.doi.org/10.1056/NEJMra1112830
[16] Ng, W.K.Y., Rosenblatt, Y., Brock, G.B., O’Gorman, D.B. and Gan, B.S. (2010) Phosphodiesterase Inhibitors in Vascular Ischemia: A Case Report and Review of Their Use in Ischemic Conditions. Canadian Journal of Plastic Surgery, 18, e5-e9.
[17] Senthilkumar, A., Smith, R.D., Khitha, J., et al. (2007) Sildenafil Promotes Ischemia-Induced Angiogenesis through a PKG-Dependent Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1947-1954. http://dx.doi.org/10.1161/ATVBAHA.107.147421
[18] Ulusoy, M.G., Uysal, A., Kocer, U., et al. (2005) Improved Flap Viability with Site-Specific Delivery of Sildenafil Citrate Using Fibrin Glue. Annals of Plastic Surgery, 55, 292-296.
http://dx.doi.org/10.1097/01.sap.0000175483.35073.ea
[19] Sarifakioglu, N., Gokrem, S., Ates, L., Akbuga, U.B. and Aslan, G. (2004) The Influence of Sildenafil on Random Skin Flap Survival in Rats: An Experimental Study. British Journal of Plastic Surgery, 57, 769-772. http://dx.doi.org/10.1016/j.bjps.2004.04.014
[20] Tsai, J.W., Ayubi, F.S., Hart, K.L., et al. (2008) Evaluation of the Effect of Sildenafil and Vascular Endothelium Growth Factor Combination Treatment on Skin Flap Survival in Rats. Aesthetic Plastic Surgery, 32, 624-631. http://dx.doi.org/10.1007/s00266-008-9166-2

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.